Statement 10 Mar 2022

Statement delivered at Panel Discussion on Universal Access to Vaccines – 20th meeting, 49th Regular Session of Human Rights Council

On 10 March 2022, IFPMA Director-General, Thomas Cueni, was invited to address a Panel discussion on ensuring equitable, affordable, timely and universal access for all countries to vaccines in response to the COVID-19 pandemic. The panel discussion took place at the 49th Regular Session of the Human Rights Council.

Statement 8 Mar 2022

Global Pandemic Preparedness Summit & CEPI Replenishment

8 March 2022 – We welcome the Global Pandemic Preparedness Summit on 7-8 March 2022 as a key milestone in rallying efforts to foster development of new vaccines within 100 days of a future pandemic being identified and ensuring their fair and equitable distribution around the world. We hope the Coalition for Epidemic Preparedness Innovations...

Expert insight 7 Mar 2022

What it takes to enable tech transfer partnerships

Technology transfer partnerships have been the cornerstone in the fight against the COVID-19 pandemic, enabling rapid scaling of health innovations but also raising new challenges.

Statement 2 Mar 2022

Pharmaceutical industry response to the crisis in Ukraine

2 March 2022 – As the situation in Ukraine continues to cause unimaginable suffering, our thoughts are with the people in Ukraine. Overcoming the challenges that this unprecedented humanitarian crisis poses for patients is our main concern. We are supporting the efforts of our sister regional organization – EFPIA – to ensure vital medicines reach...

Expert insight 2 Mar 2022

The Biopharmaceutical Industry’s Three Priorities to Urgently Increase COVID-19 Vaccine Access

As the focus of the global COVID-19 pandemic response shifts downstream from the development and production of vaccines to vaccination campaigns themselves, IFPMA Director-General Thomas Cueni lays out the biopharmaceutical industry’s three new overarching priorities.

Report 28 Feb 2022

Biopharmaceutical Industry’s Global Policy Principles on Digital Health

Today’s global health challenges and priorities require innovative approaches, including digital health and data-driven solutions. These solutions have proven their real world value by helping to combat COVID-19. At the same time, the pandemic has reinforced how critical it is to accelerate the digitalization of health systems around the world, and to have appropriate policies and resources that enable digital health benefits to reach all who need them.

Position paper 25 Feb 2022

In-country testing of Advanced Therapy Medicinal Products

This paper discusses specifics of ATMPs, where traditional in-country testing is challenging, outlining existing control strategies to detect potential issues, with recommendations to waive in-country testing without compromising product safety, quality and efficacy and in compliance with requirements, i.e., by recognition of certificates from countries with mature National Regulatory Authorities (NRAs).

Press release 25 Feb 2022

Three priorities to urgently increase access to COVID-19 vaccines

To support the global effort to develop and manufacture safe and effective COVID-19 vaccines and treatments, innovative biopharmaceutical companies will continue to work with all relevant stakeholders on three overarching priorities and supporting activities.

Video 17 Feb 2022

AMATA Video Statement: Calling AU leaders to build on momentum for the African Medicines Agency at the 35th AU Summit

As heads of state and government gathered at the 35th African Union Summit (5-6 February 2022), IFPMA as part of the African Medicines Agency Treaty Alliance (AMATA) applauded the momentum reached so far on the ratification and implementation of the AMA.

Position paper 7 Feb 2022

Use of electronic labeling

This information is a culmination of clinical development data and post-marketing learnings and data, translated into descriptive text for Healthcare Professionals (HCPs) and in some cases specifically for the patient.

External study 1 Feb 2022

AMR Industry Alliance 2021 Progress Report

In our third Progress Report, Alliance members provide detailed data presenting valuable insights into industry progress on AMR and show some encouraging areas of progress and innovation.

Press release 1 Feb 2022

Taking action on AMR: Largest life sciences sector coalition shows leadership in R&D, appropriate use and access to antibiotics and responsible manufacturing

Today the AMR Industry Alliance released its latest Progress Report, reflecting on collective achievements from the life sciences industry to minimize the spread of antimicrobial resistance (AMR).